LINCS: L-NAME (a NO synthase inhibitor) In the treatment of refractory Cardiogenic Shock A prospective randomized study
Open Access
- 1 July 2003
- journal article
- clinical trial
- Published by Oxford University Press (OUP)
- Vol. 24 (14) , 1287-1295
- https://doi.org/10.1016/s0195-668x(03)00193-3
Abstract
Aims To evaluate the effect of L-NAME (a nitric oxide syntahse inhibitor) in the treatment of refractory cardiogenic shock. Methods and results We enrolled 30 consecutive patients with refractory cardiogenic shock (systolic blood pressure that deteriorated progressively to n=15, control group) or to supportive care in addition to L-NAME (1mg/Kg bolus and 1mg/Kg/h continuous IV drip for 5h n=15). Death at one month was 27% in the L-NAME group vs. 67% in the control group (p=0.008). Unaugmented mean arterial blood pressure at 24 h from randomization was 86±20mmHg in the L-NAME group vs. 66±13mmHg in the control group (p=0.004). Urine output increased at 24h by 135±78cc/h in the L-NAME group vs a decrease of 12±87cc/h in the control group (pConclusions The results of the present study further support our previous observation that NO synthase inhibitors are beneficial in the treatment of patients with refractory cardiogenic shock.Keywords
This publication has 0 references indexed in Scilit: